Trials / Completed
CompletedNCT00570752
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | |
| DRUG | BMS-582949 | |
| DRUG | Atorvastatin | |
| DRUG | Statin |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2010-11-01
- Completion
- 2010-12-01
- First posted
- 2007-12-11
- Last updated
- 2015-12-07
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00570752. Inclusion in this directory is not an endorsement.